Healthcare company Haleon has initiated a voluntary recall of two Robitussin Honey products sold across the country, citing potential microbial contamination that poses a risk of severe or life-threatening adverse events, especially for immunocompromised individuals. The recall, affecting eight lot numbers of “Robitussin Honey CF Max Day Adult” and “Robitussin Honey CF Max Nighttime Adult,” was announced through a press release shared by the FDA.
Below are the lot numbers:
- ROBITUSSIN HONEY CF MAX DAY ADULT 4OZ: Lot number T10810
- ROBITUSSIN HONEY CF MAX DAY ADULT 8OZ: Lot numbers T08730, T08731, T08732, T08733, T10808
- ROBITUSSIN HONEY CF MAX NT ADULT 8OZ: Lot numbers T08740, T08742
Haleon emphasized the serious consequences for those with weakened immune systems, stating that consuming the recalled products could result in fungemia or disseminated fungal infection. While non-immunocompromised individuals are less likely to face life-threatening infections, the company acknowledged the possibility of infections requiring medical intervention.
As of now, Haleon has not received any reports of adverse events related to the recall. Consumers are urged to cease using the recalled products immediately. Additionally, Haleon advises individuals to contact their doctor if they encounter issues linked to using the affected Robitussin cough syrups.
McCann Dillon Jaffe & Lamb, LLC has been obtaining justice for those injured by defective or dangerous products for decades. For more information, call 215-569-8488 or contact us online to schedule a free consultation. Located in Philadelphia and Abington, Pennsylvania, as well as Wilmington, Delaware, we serve clients throughout the surrounding areas.